1. What is Microbiome Plus+ Gastrointestinal?
Microbiome Plus+ Gastrointestinal is a more complete gastrointestinal health dietary supplement that provides natural prebiotic fiber (scFOS) and the probiotic L. reuteri NCIMB 30242 which work together to maintain the balance of healthy bacteria in your gut and support normal digestive function.*
2. What are the benefits of Microbiome Plus+ Gastrointestinal?
Supports gastrointestinal and immune health*
Maintains balance of healthy bacteria*
Supports normal inflammatory response*
Supports healthy bile metabolism*
Synbiotic formulation with pre and probiotics*
3. Who should take Microbiome Plus+ Gastrointestinal?
Microbiome Plus+ Gastrointestinal is intended for patients looking to support their gastrointestinal health with a more complete natural dietary supplement.
4. How does Microbiome Plus+ Gastrointestinal work?
The probiotic in Microbiome Plus+ Gastrointestinal has been shown in clinical trials to help support normal inflammatory response in addition to supporting digestive health.*
scFOS is a natural prebiotic fiber that supports a healthy gastrointestinal tract by promoting digestive function, immune health, the growth of healthy bacteria, natural intestinal mechanical barriers, and gut integrity.*
Microbiome Plus+ Gastrointestinal combines these two ingredients to provide more complete gastrointestinal health support.* Not only does scFOS support digestive function but as a prebiotic helps L. reuteri NCIMB 30242 to support normal gastrointestinal function.*
5. Is the prebiotic fiber in Microbiome Plus+ Gastrointestinal right for me?
Microbiome Plus+ Gastrointestinal provides the highest quality, bioavailable natural source of short chain fructooligosaccarides (scFOS). scFOS is a natural non-digestible prebiotic fiber that supports a healthy gastrointestinal tract by promoting digestive function, immune health, the growth of healthy bacteria, intestinal barrier function and gut integrity.* The scFOS in Microbiome Plus+ Gastrointestinal is a gentle, well tolerated fiber that has no aftertaste and like all Microbiome Plus+ active ingredients is non-GMO and allergen free.
6. Is Microbiome Plus+ Gastrointestinal a drug?
No. Microbiome Plus+ Gastrointestinal is a more complete dietary supplement that does not require a prescription.
8. If I am a Healthcare Professional can I get a discount?
Yes. If you are a health professional please contact us for special rates. Must have proof of health practice business. Visit www.microbiomeplus.com or call 1-800-214-0031.
9. Is Microbiome Plus+ Gastrointestinal safe?
Yes. The ingredients in Microbiome Plus+ Gastrointestinal have been shown to be safe in clinical trials.
10. Is there anyone who should not take Microbiome Plus+ Gastrointestinal?
Microbiome Plus+ Gastrointestinal should not be used if pregnant, trying to get pregnant or nursing. Microbiome Plus+ Gastrointestinal is not intended for those under 18 years of age. Discuss with your doctor if you have nausea, fever, vomiting, bloody diarrhea, severe abdominal pain, an immune-compromised condition.
11. Are there any side effects?
As with other probiotic supplements patients may experience digestive discomfort, gas or bloating.
12. What should I do if I experience an unexpected reaction to Microbiome Plus+ Gastrointestinal?
Report any unexpected reaction after starting Microbiome Plus+ Gastrointestinal by calling 1-800-214-0031.
13. How do I take Microbiome Plus+ Gastrointestinal?
Microbiome Plus+ Gastrointestinal should be taken twice daily with meals for best results (e.g. with lunch and dinner) but can be taken without food as well.
14. What makes Microbiome Plus+ Gastrointestinal professional grade?
Microbiome Plus+ Gastrointestinal uses professional grade and quality ingredients:
Full recommended daily dose*
Sourced from nature and allergen free*
From renewable and sustainable sources*
Developed by doctors*
15. Is Microbiome Plus+ Gastrointestinal allergen free?
16. How should Microbiome Plus+ Gastrointestinal be stored?
Microbiome Plus+ Gastrointestinal does not require refrigeration and should be stored in a cool dry place.
*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
- Jones M.L., Martoni,C.J., Ganopolsky,J.G., Sulemankhil,I., & Prakash,S. Improvement of gastrointestinal health status in subjects consuming L. reuteri NCIMB 30242 capsules: a post hoc analysis of a randomized controlled trial. Expert Opinion on Biological Therapy (accepted), (2013).
- Jones,M.L., Martoni,C.J., & Prakash,S. Letter to the editor regarding the report of Duboc et al: connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel disease. Gut(2012).
- Jones,M.L., Martoni,C.J., & Prakash,S. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur. J Clin. Nutr. 66, 1234-1241 (2012).
- Campbell,J.M., Fahey,G.C., Jr., & Wolf,B.W. Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats. J Nutr. 127, 130-136 (1997).
- Environ International Corporation. Short-Chain Fructooligosaccharide GRAS Notice. GRN000044. 2000. Ref Type: Report
- Macfarlane,G.T. & Cummings,J.H. Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? West J Med 171, 187-191 (1999).
- Oli,M.W., Petschow,B.W., & Buddington,R.K. Evaluation of fructooligosaccharide supplementation of oral electrolyte solutions for treatment of diarrhea: recovery of the intestinal bacteria. Dig. Dis Sci. 43, 138-147 (1998).
- Cherbut,C., Michel,C., & Lecannu,G. The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats. J Nutr. 133, 21-27 (2003).
- Bouhnik,Y. et al. The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study. Am. J Clin. Nutr. 80, 1658-1664 (2004).
- Bouhnik,Y., Raskine,L., Simoneau,G., Paineau,D., & Bornet,F. The capacity of short-chain fructo-oligosaccharides to stimulate faecal bifidobacteria: a dose-response relationship study in healthy humans. Nutr. J 5, 8 (2006).
- Jones,M.L., Martoni,C.J., Parent,M., & Prakash,S. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br. J. Nutr.1-9 (2011).
- Jones,M.L., Martoni,C.J., & Prakash,S. Oral Supplementation With Probiotic L. reuteri NCIMB 30242 Increases Mean Circulating 25-Hydroxyvitamin D: A Post Hoc Analysis of a Randomized Controlled Trial. J Clin. Endocrinol. Metab 98, 2944-2951 (2013).
- Yoon,S.S. & Sun,J. Probiotics, nuclear receptor signaling, and anti-inflammatory pathways. Gastroenterol. Res. Pract. 2011, 971938 (2011).
- Sayin,S.I. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17, 225-235 (2013).
- Swann,J.R. et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc. Natl. Acad. Sci. U. S. A 108 Suppl 1, 4523-4530 (2011).
- Inagaki,T. et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. U. S. A 103, 3920-3925 (2006).
- Hofmann,A.F. & Eckmann,L. How bile acids confer gut mucosal protection against bacteria. Proc. Natl. Acad. Sci. U. S. A 103, 4333-4334 (2006).
- Duboc,H. et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut(2012).
- Duboc,H. et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol. Motil. 24, 513-517 (2012).
- Ogilvie,L.A. & Jones,B.V. Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: a mechanism and marker of disease? Gut 61, 1642-1643 (2012).
- Clemente,J.C., Ursell,L.K., Parfrey,L.W., & Knight,R. The impact of the gut microbiota on human health: an integrative view. Cell 148, 1258-1270 (2012).
- Blaser,M.J. & Falkow,S. What are the consequences of the disappearing human microbiota? Nat. Rev. Microbiol 7, 887-894 (2009).
- Dominguez-Bello,M.G. et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl. Acad. Sci. U. S. A 107, 11971-11975 (2010).
- The Human Microbiome Project. Baylor College of Medicine . 2013. 8-8-2013. Ref Type: Electronic Citation
- Palmer,C., Bik,E.M., DiGiulio,D.B., Relman,D.A., & Brown,P.O. Development of the human infant intestinal microbiota. PLoS. Biol. 5, e177 (2007).
- Turnbaugh,P.J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-1031 (2006).
- Brestoff,J.R. & Artis,D. Commensal bacteria at the interface of host metabolism and the immune system. Nat. Immunol. 14, 676-684 (2013).
- Marchesi,J.R. et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome. Res. 6, 546-551 (2007).
- Holmes,E. et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453, 396-400 (2008).
- Koeth,R.A. et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med 19, 576-585 (2013).
- Tang,W.H. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J Med 368, 1575-1584 (2013).
- Ley,R.E., Turnbaugh,P.J., Klein,S., & Gordon,J.I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022-1023 (2006).
- Walter,J. & Ley,R. The human gut microbiome: ecology and recent evolutionary changes. Annu. Rev. Microbiol 65, 411-429 (2011).
- Wu,G.D. et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 334, 105-108 (2011).
- Jones,M.L., Martoni,C.J., Tamber,S., Parent,M., & Prakash,S. Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: A randomized, placebo-controlled, double-blind study. Food Chem Toxicol. 2012. Ref Type: In Press
- Jones,M.L., Martoni,C.J., Di,P.E., Simon,R.R., & Prakash,S. Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial. Regul. Toxicol. Pharmacol. 63, 313-320 (2012).
- Micropharma Limited. Lactobacillus reuteri NCIMB 30242 GRAS Notice. GRN000440. 2012. Ref Type: Report